dehydroepiandrosterone has been researched along with Local Neoplasm Recurrence in 7 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 7.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 6.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "A 58-year-old man had adrenocortical carcinoma in the right adrenal gland." | 5.30 | Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999) |
| "About one third of unselected postmenopausal women with advanced breast cancer respond to treatment with aminoglutethimide and hydrocortisone, but they all eventually relapse, and further progression of disease occurs." | 3.67 | Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. ( Dowsett, M; Harris, AL; Jeffcoate, SL; Smith, IE, 1984) |
| " Our review determined that amongst published RCTs, no studies have aimed to assess for breast cancer recurrence; however among the studies observing for serious adverse effects of vaginal estrogen preparations, none have reported an increased incidence." | 3.01 | A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors. ( Hussain, I; Talaulikar, VS, 2023) |
| " While this regimen effectively blocked adrenal function, it was complicated by a drug interaction in which aminoglutethimide accelerated the metabolism and reduced the bioavailability of dexamethasone." | 2.36 | Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer. ( Harvey, H; Kendall, J; Lipton, A; Ruby, EB; Samojlik, E; Santen, RJ; Wells, SA, 1977) |
| "A 58-year-old man had adrenocortical carcinoma in the right adrenal gland." | 1.30 | Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999) |
| "The major focus in prostate cancer therapy currently is the role of the adrenal androgens." | 1.29 | Basis for hormonal management of advanced prostate cancer. ( Geller, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Hussain, I | 1 |
| Talaulikar, VS | 1 |
| Dowsett, M | 1 |
| Harris, AL | 1 |
| Smith, IE | 1 |
| Jeffcoate, SL | 1 |
| Shoji, M | 1 |
| Ohkawa, K | 1 |
| Hosoda, H | 1 |
| Hachiya, S | 1 |
| Geller, J | 1 |
| O'Shaughnessy, JA | 1 |
| Seki, M | 1 |
| Nomura, K | 1 |
| Hirohara, D | 1 |
| Kanazawa, M | 1 |
| Sawada, T | 1 |
| Takasaki, K | 1 |
| Demura, H | 1 |
| Santen, RJ | 1 |
| Samojlik, E | 1 |
| Lipton, A | 1 |
| Harvey, H | 1 |
| Ruby, EB | 1 |
| Wells, SA | 1 |
| Kendall, J | 1 |
2 reviews available for dehydroepiandrosterone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
A systematic review of randomised clinical trials - The safety of vaginal hormones and selective estrogen receptor modulators for the treatment of genitourinary menopausal symptoms in breast cancer survivors.
Topics: Breast Neoplasms; Cancer Survivors; Dehydroepiandrosterone; Estrogens; Female; Humans; Menopause; Ne | 2023 |
Kinetic, hormonal and clinical studies with aminoglutethimide in breast cancer.
Topics: Adrenocorticotropic Hormone; Aldosterone; Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehy | 1977 |
5 other studies available for dehydroepiandrosterone and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
Topics: Aminoglutethimide; Androstenedione; Breast Neoplasms; Dehydroepiandrosterone; Estradiol; Estrone; Fe | 1984 |
Production of steroids in one case of granulosa cell tumor in culture.
Topics: Cells, Cultured; Dehydroepiandrosterone; Estradiol; Female; Gonadal Steroid Hormones; Granulosa Cell | 1980 |
Basis for hormonal management of advanced prostate cancer.
Topics: Androstenedione; Animals; Dehydroepiandrosterone; Dihydrotestosterone; Humans; Male; Neoplasm Recurr | 1993 |
Chemoprevention of breast cancer.
Topics: Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Carci | 1996 |
Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Dehydroepiandro | 1999 |